Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma

Published:2024-04 Issue:4 Volume:8 Page:
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:HemaSphere

Author:

Merryman Reid W.¹^ORCID,Rhoades Justin²,Xiong Kan²,Redd Robert A.³,Antel Katherine¹⁴,An Hyun Hwan¹,McDonough Mikaela¹,Guerrero Liliana¹,Crnjac Andela²^ORCID,Sridhar Sainetra²,Blewett Timothy²,Cheng Ju²,Dahi Parastoo B.⁵,Nieto Yago⁶,Joyce Robin M.⁷,Chen Yi‐Bin⁸,Herrera Alex F.⁹,Armand Philippe¹,Murakami Mark¹,Adalsteinsson Viktor A.²

Affiliation:

1. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

2. Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA

3. Department of Data Science Dana‐Farber Cancer Institute Boston Massachusetts USA

4. Institute for Infectious Disease and Molecular Medicine University of Cape Town Cape Town South Africa

5. Department of Medicine, Adult Bone Marrow Transplant Service Memorial Sloan‐Kettering Cancer Center New York City New York USA

6. Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas USA

7. Department of Hematologic Malignancy Beth Israel Deaconess Medical Center Boston Massachusetts USA

8. Bone Marrow Transplantation Program Massachusetts General Hospital Boston Massachusetts USA

9. Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hem3.47

Reference14 articles.

1. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

2. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

3. Phased variants improve DLBCL minimal residual disease detection at the end of therapy;Kurtz DM;J Clin Oncol,2021

4. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

5. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA